As senior vice president of product innovation & strategy, Kevin Fletemeyer is responsible for product and innovation across the company, partnering with leadership to drive execution pathways to deliver on enterprise strategy.
Prior to joining Prime Therapeutics upon the completion of Prime’s acquisition of Magellan Rx. Fletemeyer served 14 years with Magellan Health, holding several executive-level positions primarily within Magellan Rx. Most recently, Fletemeyer served as chief strategy officer for Magellan Rx, which included PBM supply chain management, pricing and underwriting, industry partnerships, corporate development and M&A support, and advanced analytics. In addition, he served as interim general manager of the PBM business unit. Prior to that, Fletemeyer was Magellan Rx chief financial officer (CFO) responsible for the management and direction of all financial affairs of the company, including business strategy and operational effectiveness. Previous to this, he was the CFO for Magellan Medicaid Administration, which contracts with 28 state Medicaid programs and the District of Columbia.
Fletemeyer has extensive experience in operational finance across multiple industries and multiple sectors within specialty health care management, including pharmacy, behavioral health and radiology. Before joining Magellan in 2008, he worked for several years in the finance sector, holding various positions at Green Tree Servicing and JPMorgan Chase.
Fletemeyer obtained his Master of Business Administration degree from Arizona State University’s WP Carey School of Business and holds a Bachelor of Science degree in finance and business process management from Indiana University.